Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 6:48 PM
Ignite Modification Date: 2025-12-25 @ 4:20 PM
NCT ID: NCT02439957
Description: None
Frequency Threshold: 0
Time Frame: None
Study: NCT02439957
Study Brief: A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Treatment 1 100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily. None None 0 3 3 3 View
Treatment 2 900 mg valganciclovir (vGCV; two 450 mg tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly. None None 0 3 1 3 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.1) View
Muscle spasms SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (23.1) View
Alanine aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (23.1) View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.1) View
Hot flush SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (23.1) View
Flatulence SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.1) View
Hypophosphataemia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (23.1) View
Insomnia SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (23.1) View
Incision site complication SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (23.1) View
Tachycardia SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (23.1) View
Basal cell carcinoma SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA (23.1) View
Ingrowing nail SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (23.1) View
Abdominal discomfort SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.1) View
Aspartate aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (23.1) View
Diarrhoea intermittent SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.1) View
Nightmare SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (23.1) View